These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9533548)

  • 1. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.
    Zamboni WC; Gajjar AJ; Heideman RL; Beijnen JH; Rosing H; Houghton PJ; Stewart CF
    Clin Cancer Res; 1998 Mar; 4(3):783-9. PubMed ID: 9533548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma.
    Freeman BB; Iacono LC; Panetta JC; Gajjar A; Stewart CF
    Neuro Oncol; 2006 Apr; 8(2):89-95. PubMed ID: 16461424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.
    Stewart CF; Iacono LC; Chintagumpala M; Kellie SJ; Ashley D; Zamboni WC; Kirstein MN; Fouladi M; Seele LG; Wallace D; Houghton PJ; Gajjar A
    J Clin Oncol; 2004 Aug; 22(16):3357-65. PubMed ID: 15310781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
    Zackrisson AL; Malmström H; Peterson C
    Eur J Clin Pharmacol; 2002 May; 58(2):103-8. PubMed ID: 12012141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.
    Zamboni WC; Gajjar AJ; Mandrell TD; Einhaus SL; Danks MK; Rogers WP; Heideman RL; Houghton PJ; Stewart CF
    Clin Cancer Res; 1998 Oct; 4(10):2537-44. PubMed ID: 9796988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
    Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
    Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study assessing a seven-day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer.
    Tran HC; Gardner S; Weiner HL; Liebes LF; Finlay JL
    J Oncol Pharm Pract; 2014 Jun; 20(3):229-32. PubMed ID: 23929729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection.
    Bai F; Kirstein MN; Hanna SK; Iacono LC; Johnston B; Stewart CF
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Feb; 784(2):225-32. PubMed ID: 12505770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.
    Herben VM; ten Bokkel Huinink WW; Schot ME; Hudson I; Beijnen JH
    Anticancer Drugs; 1998 Jun; 9(5):411-8. PubMed ID: 9660538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.
    Baker SD; Heideman RL; Crom WR; Kuttesch JF; Gajjar A; Stewart CF
    Cancer Chemother Pharmacol; 1996; 37(3):195-202. PubMed ID: 8529278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
    Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
    Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topotecan lacks third space sequestration.
    Gelderblom H; Loos WJ; Verweij J; de Jonge MJ; Sparreboom A
    Clin Cancer Res; 2000 Apr; 6(4):1288-92. PubMed ID: 10778953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
    Abbruzzese JL; Madden T; Sugarman SM; Ellis AL; Loughlin S; Hess KR; Newman RA; Zwelling LA; Raber MN
    Clin Cancer Res; 1996 Sep; 2(9):1489-97. PubMed ID: 9816325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity.
    Stewart CF; Baker SD; Heideman RL; Jones D; Crom WR; Pratt CB
    J Clin Oncol; 1994 Sep; 12(9):1946-54. PubMed ID: 8083716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors.
    Zamboni WC; Bowman LC; Tan M; Santana VM; Houghton PJ; Meyer WH; Pratt CB; Heideman RL; Gajjar AJ; Pappo AS; Stewart CF
    Cancer Chemother Pharmacol; 1999; 43(6):454-60. PubMed ID: 10321504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of topotecan.
    Herben VM; ten Bokkel Huinink WW; Beijnen JH
    Clin Pharmacokinet; 1996 Aug; 31(2):85-102. PubMed ID: 8853931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
    Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic analysis of topotecan in pediatric cancer patients.
    Schaiquevich P; Panetta JC; Iacono LC; Freeman BB; Santana VM; Gajjar A; Stewart CF
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6703-11. PubMed ID: 18006771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion.
    Zamboni WC; Houghton PJ; Johnson RK; Hulstein JL; Crom WR; Cheshire PJ; Hanna SK; Richmond LB; Luo X; Stewart CF
    J Pharmacol Exp Ther; 1998 Jan; 284(1):89-94. PubMed ID: 9435165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I and pharmacokinetic study of intraperitoneal topotecan.
    Hofstra LS; Bos AM; de Vries EG; van der Zee AG; Beijnen JH; Rosing H; Mulder NH; Aalders JG; Willemse PH
    Br J Cancer; 2001 Nov; 85(11):1627-33. PubMed ID: 11742479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.